Home Stock Ideas Long Ideas Healthcare  Summary Olema Pharmaceuticals is rated a cautious buy, with upside potential tied to pivotal OPERA-01 Phase 3 trial results expected in fall 2026. Palazestrant differentiates itself as a CERAN with superior mechanistic action, favorable pharmacokinetics, and strong combinability, targeting ER+/HER2- breast cancer. Current valuation is conservative, reflecting early-stage data, competitive risks, and limited probability of success, but even the base case offers material upside. OLMA is well-capitalized to reach its next major catalyst, though commercialization funding and dilution remain key risks if pivotal data are not positive. Looking for a portfolio of ideas like this one? Members of The Total Pharma Tracker get exclusive access to our subscriber-only portfolios. Learn More » Getty Images Olema Pharmaceuticals ( OLMA ) published decent trial results in October last year, but the stock dropped ~30%.…